vs

Side-by-side financial comparison of Celanese Corp (CE) and PACS Group, Inc. (PACS). Click either name above to swap in a different company.

Celanese Corp is the larger business by last-quarter revenue ($2.2B vs $1.4B, roughly 1.6× PACS Group, Inc.). PACS Group, Inc. runs the higher net margin — 4.4% vs 0.6%, a 3.8% gap on every dollar of revenue. On growth, PACS Group, Inc. posted the faster year-over-year revenue change (18.4% vs -7.0%). Over the past eight quarters, PACS Group, Inc.'s revenue compounded faster (20.5% CAGR vs -8.1%).

Celanese Corporation, formerly known as Hoechst Celanese, is an American technology and specialty materials company headquartered in Irving, Texas. It is a Fortune 500 corporation. The company is the world's leading producer of acetic acid, producing about 1.95 million tonnes per year, representing approximately 20% of global production. Celanese is also the world's largest producer of vinyl acetate monomer (VAM).

CE vs PACS — Head-to-Head

Bigger by revenue
CE
CE
1.6× larger
CE
$2.2B
$1.4B
PACS
Growing faster (revenue YoY)
PACS
PACS
+25.4% gap
PACS
18.4%
-7.0%
CE
Higher net margin
PACS
PACS
3.8% more per $
PACS
4.4%
0.6%
CE
Faster 2-yr revenue CAGR
PACS
PACS
Annualised
PACS
20.5%
-8.1%
CE

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
CE
CE
PACS
PACS
Revenue
$2.2B
$1.4B
Net Profit
$14.0M
$59.7M
Gross Margin
19.1%
Operating Margin
4.0%
7.0%
Net Margin
0.6%
4.4%
Revenue YoY
-7.0%
18.4%
Net Profit YoY
100.7%
3022.5%
EPS (diluted)
$0.13
$0.42

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
CE
CE
PACS
PACS
Q4 25
$2.2B
$1.4B
Q3 25
$2.4B
$1.3B
Q2 25
$2.5B
$1.3B
Q1 25
$2.4B
$1.3B
Q4 24
$2.4B
$1.1B
Q3 24
$2.6B
$1.0B
Q2 24
$2.7B
$981.4M
Q1 24
$2.6B
$934.3M
Net Profit
CE
CE
PACS
PACS
Q4 25
$14.0M
$59.7M
Q3 25
$-1.4B
$52.4M
Q2 25
$199.0M
$51.0M
Q1 25
$-21.0M
$28.5M
Q4 24
$-1.9B
$1.9M
Q3 24
$116.0M
$15.6M
Q2 24
$155.0M
$-10.9M
Q1 24
$121.0M
$49.1M
Gross Margin
CE
CE
PACS
PACS
Q4 25
19.1%
Q3 25
21.5%
Q2 25
21.1%
Q1 25
19.9%
Q4 24
22.7%
Q3 24
23.5%
17.1%
Q2 24
24.2%
22.3%
Q1 24
21.2%
21.2%
Operating Margin
CE
CE
PACS
PACS
Q4 25
4.0%
7.0%
Q3 25
-52.7%
6.4%
Q2 25
9.2%
6.2%
Q1 25
7.0%
3.8%
Q4 24
-59.3%
1.7%
Q3 24
9.4%
2.2%
Q2 24
9.4%
0.1%
Q1 24
8.0%
8.6%
Net Margin
CE
CE
PACS
PACS
Q4 25
0.6%
4.4%
Q3 25
-56.1%
3.9%
Q2 25
7.9%
3.9%
Q1 25
-0.9%
2.2%
Q4 24
-80.8%
0.2%
Q3 24
4.4%
1.5%
Q2 24
5.8%
-1.1%
Q1 24
4.6%
5.3%
EPS (diluted)
CE
CE
PACS
PACS
Q4 25
$0.13
$0.42
Q3 25
$-12.39
$0.32
Q2 25
$1.81
$0.31
Q1 25
$-0.19
$0.17
Q4 24
$-17.50
$-0.03
Q3 24
$1.06
$0.10
Q2 24
$1.41
$-0.07
Q1 24
$1.10
$0.38

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
CE
CE
PACS
PACS
Cash + ST InvestmentsLiquidity on hand
$197.0M
Total DebtLower is stronger
$11.4B
$353.2M
Stockholders' EquityBook value
$4.0B
$946.8M
Total Assets
$21.7B
$5.6B
Debt / EquityLower = less leverage
2.81×
0.37×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
CE
CE
PACS
PACS
Q4 25
$197.0M
Q3 25
$355.7M
Q2 25
$294.2M
Q1 25
$287.5M
Q4 24
$157.7M
Q3 24
$49.5M
Q2 24
$73.4M
Q1 24
$81.2M
Total Debt
CE
CE
PACS
PACS
Q4 25
$11.4B
$353.2M
Q3 25
$11.7B
Q2 25
$12.7B
Q1 25
$12.4B
Q4 24
$11.1B
$411.9M
Q3 24
$11.3B
Q2 24
$11.1B
Q1 24
$11.0B
Stockholders' Equity
CE
CE
PACS
PACS
Q4 25
$4.0B
$946.8M
Q3 25
$4.0B
$871.3M
Q2 25
$5.3B
$806.8M
Q1 25
$5.2B
$750.2M
Q4 24
$5.2B
$709.6M
Q3 24
$7.3B
$660.0M
Q2 24
$7.2B
$572.1M
Q1 24
$7.1B
$128.0M
Total Assets
CE
CE
PACS
PACS
Q4 25
$21.7B
$5.6B
Q3 25
$22.2B
$5.6B
Q2 25
$23.7B
$5.5B
Q1 25
$23.2B
$5.5B
Q4 24
$22.9B
$5.2B
Q3 24
$25.9B
$4.5B
Q2 24
$25.8B
$3.9B
Q1 24
$26.0B
$3.9B
Debt / Equity
CE
CE
PACS
PACS
Q4 25
2.81×
0.37×
Q3 25
2.95×
Q2 25
2.41×
Q1 25
2.39×
Q4 24
2.14×
0.58×
Q3 24
1.56×
Q2 24
1.54×
Q1 24
1.56×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
CE
CE
PACS
PACS
Operating Cash FlowLast quarter
$252.0M
$-3.4M
Free Cash FlowOCF − Capex
$168.0M
FCF MarginFCF / Revenue
7.6%
Capex IntensityCapex / Revenue
3.8%
Cash ConversionOCF / Net Profit
18.00×
-0.06×
TTM Free Cash FlowTrailing 4 quarters
$803.0M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
CE
CE
PACS
PACS
Q4 25
$252.0M
$-3.4M
Q3 25
$447.0M
$204.8M
Q2 25
$410.0M
$52.6M
Q1 25
$37.0M
$150.2M
Q4 24
$494.0M
$64.6M
Q3 24
$79.0M
$209.2M
Q2 24
$292.0M
$34.8M
Q1 24
$101.0M
$58.8M
Free Cash Flow
CE
CE
PACS
PACS
Q4 25
$168.0M
Q3 25
$383.0M
Q2 25
$317.0M
Q1 25
$-65.0M
Q4 24
$389.0M
Q3 24
$-9.0M
Q2 24
$187.0M
Q1 24
$-36.0M
FCF Margin
CE
CE
PACS
PACS
Q4 25
7.6%
Q3 25
15.8%
Q2 25
12.5%
Q1 25
-2.7%
Q4 24
16.4%
Q3 24
-0.3%
Q2 24
7.1%
Q1 24
-1.4%
Capex Intensity
CE
CE
PACS
PACS
Q4 25
3.8%
Q3 25
2.6%
Q2 25
3.7%
Q1 25
4.3%
Q4 24
4.4%
Q3 24
3.3%
Q2 24
4.0%
Q1 24
5.2%
Cash Conversion
CE
CE
PACS
PACS
Q4 25
18.00×
-0.06×
Q3 25
3.91×
Q2 25
2.06×
1.03×
Q1 25
5.28×
Q4 24
33.78×
Q3 24
0.68×
13.39×
Q2 24
1.88×
Q1 24
0.83×
1.20×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

CE
CE

Engineered Materials$1.3B58%
Acetyl Chain$940.0M43%

PACS
PACS

Segment breakdown not available.

Related Comparisons